Zobrazeno 1 - 10
of 24
pro vyhledávání: ''
Autor:
Gabriele Curcio, Floriana Barbera, Fabio Tuzzolino, Pier Giulio Conaldi, Riccardo Volpes, Giada Pietrosi, Giovanna Russelli, Giovanni Vizzini, Alessia Gallo
Publikováno v:
Transplant Infectious Disease
The hepatitis C virus mainly infects the liver but is also able to infect and replicate in other body compartments by creating an extra‐hepatic reservoir that may influence the persistence of the infection after transplantation. It is unknown wheth
Autor:
Leonardo Centonze, Angelo Calini, Roberto Fumagalli, Marco Merli, Sara Santambrogio, Mila Valsecchi, Massimo Puoti, Riccardo De Carlis, Luciano De Carlis, Vincenzo Buscemi, Andrea Lauterio, Maurizio Bottiroli
Publikováno v:
Transplant Infectious Disease
Although immunosuppressed patients may be more prone to SARS‐CoV‐2 infection with atypical presentation, long‐term immunosuppression therapy may provide some sort of protection for severe clinical complications of COVID‐19. The interaction be
Autor:
Takashi Sugimoto, Masaya Takahashi, Katsuya Nagayama, Ryo Inose, Hideo Koh, Masayuki Hino, Katsuyuki Takahashi
Publikováno v:
Transplant Infectious Disease. 22
BACKGROUND Concomitant use of foscarnet and intravenous pentamidine can very frequently cause severe hypocalcemia. However, it is unknown whether aerosolized pentamidine has a similar adverse interaction with foscarnet. The present study was aimed at
Autor:
Giovanna Travi, Roberto Rossotti, Luciano De Carlis, Andrea Lauterio, Olivia Bargiacchi, Fabio Ferla, Marco Merli, Chiara Alcantarini, Teresa Angelini Zucchetti, Massimo Puoti
Publikováno v:
Transplant Infectious Disease. 21
Direct-acting antivirals (DAAs) demonstrated high efficacy and safety even in the post-liver transplant (LT) setting and in HIV-infected patients, but data are very limited in the early post-LT period with the most recently available DAA. Two HIV/HCV
Autor:
Michael P. Manns, H Mix, R. Costa, Martina Sterneck, H. Wedemeyer, V M Proske, Sandra Ciesek, Bjoern Nashan, Juergen Klempnauer, Ansgar W. Lohse, Benjamin Otto, M. Lüthgehetmann, T. von Hahn, Sven Pischke, Susanne Polywka
Publikováno v:
Transplant Infectious Disease. 18:326-332
Background Hepatitis C virus (HCV) infection is associated with a particularly poor outcome after liver transplantation. In December 2014, sofosbuvir/ledipasvir (SOF/LDV) fixed-dose combination (FDC) was approved for HCV genotype 1 and 4 in Europe. I
Autor:
Yasunaru Sakuma, Toshihiro Shimizu, Koji Nanmoku, Akira Kurosawa, Atsushi Miki, Takaaki Kimura, Takashi Yagisawa, Nobuo Ishikawa
Publikováno v:
Transplant Infectious Disease. 18:234-239
Background Urinary tract infection caused by human adenovirus (HAdV) after renal transplantation (RT) results in graft loss because of concomitant nephropathy and acute rejection and may result in death because of systemic dissemination. Methods We a
Autor:
David Navarro, Marisa Calabuig, José Luis Piñana, Juan Carlos Hernández-Boluda, Carlos Solano, M Á Serra
Publikováno v:
Transplant Infectious Disease. 18:89-92
Currently, a lack of consensus exists on how to manage a hepatitis C virus (HCV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ribavirin alone, or in combination with interferon, has been the mainstream therapy for H
Autor:
W.R. Kim, Zobair M. Younossi, Edward A. Pham, Jeffrey S. Glenn, Aijaz Ahmed, Radhika Kumari, Tami Daugherty, Ryan B. Perumpail, U. Wang, Robert J. Wong, John P. Higgins, H. Luong, L.D. Ha
Publikováno v:
Transplant Infectious Disease. 17:275-278
We report safety, tolerability, and 12-week sustained virologic response with half-standard dose sofosbuvir and standard-dose simeprevir combination therapy in a hepatitis C virus genotype 1a-infected liver transplant recipient on hemodialysis - unch
Autor:
A. Londero, P. Della Siega, Giovanni Villa, P. Delle Foglie, Elda Righi, Matteo Bassetti, Federico Pea, O. Giglio, Umberto Baccarani, P. Nasta, S. Bonora, S. Dal Zoppo
Publikováno v:
Transplant Infectious Disease. 17:147-153
Since the introduction of combined antiretroviral therapy, human immunodeficiency virus (HIV) infection is no longer a contraindication for solid organ transplantation. In HIV/hepatitis C virus (HCV)-coinfected patients undergoing liver transplantati
Autor:
Karim Boudjema, Marie-Clémence Verdier, C. Boglione‐Kerrien, M. Dermu, C. Jezequel, Florian Lemaitre, Eric Bellissant
Publikováno v:
Transplant Infectious Disease
Transplant Infectious Disease, 2015, 17 (1), pp.106--110. ⟨10.1111/tid.12335⟩
Transplant Infectious Disease, Wiley, 2015, 17 (1), pp.106--110. ⟨10.1111/tid.12335⟩
Transplant Infectious Disease, 2015, 17 (1), pp.106--110. ⟨10.1111/tid.12335⟩
Transplant Infectious Disease, Wiley, 2015, 17 (1), pp.106--110. ⟨10.1111/tid.12335⟩
International audience; Telaprevir is a novel NS3A/4A protease inhibitor approved in combination with ribavirin and peg-interferon alfa for the treatment of genotype-1 chronic hepatitis C. This drug is also known to be a potent cytochrome P450 3A and